Cite
HARVARD Citation
Cid, M. et al. (2022). Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases. 81 (5), pp. 653-661. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Cid, M. et al. (2022). Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Annals of the rheumatic diseases. 81 (5), pp. 653-661. [Online].